SK8552001A3 - A method for the high level expression of active lymphotoxin-'beta' receptor immunoglobulin chimeric proteins and their purification - Google Patents

A method for the high level expression of active lymphotoxin-'beta' receptor immunoglobulin chimeric proteins and their purification Download PDF

Info

Publication number: SK8552001A3
Authority: SK; Slovakia
Prior art keywords: protein; fusion; receptor; active; fragment
Prior art date: 1998-12-17

Application number

SK855-2001A

Other languages

English (en)

Slovak (sk)

Inventor

Jeffrey Browning

Konrad Miatkowski

Werner Meier

Original Assignee

Biogen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-17

Filing date

1999-12-16

Publication date

2001-12-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22345666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK8552001(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-12-16 Application filed by Biogen Inc filed Critical Biogen Inc

2001-12-03 Publication of SK8552001A3 publication Critical patent/SK8552001A3/sk

Links

238000000034 method Methods 0.000 title claims abstract description 72
102000037865 fusion proteins Human genes 0.000 title claims abstract description 41
108020001507 fusion proteins Proteins 0.000 title claims abstract description 41
238000000746 purification Methods 0.000 title abstract description 6
108060003951 Immunoglobulin Proteins 0.000 title description 11
102000018358 immunoglobulin Human genes 0.000 title description 11
108090000623 proteins and genes Proteins 0.000 claims description 70
102000004169 proteins and genes Human genes 0.000 claims description 68
235000018102 proteins Nutrition 0.000 claims description 65
230000004927 fusion Effects 0.000 claims description 54
102100040247 Tumor necrosis factor Human genes 0.000 claims description 31
238000002360 preparation method Methods 0.000 claims description 31
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 29
238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 19
238000004519 manufacturing process Methods 0.000 claims description 17
239000000203 mixture Substances 0.000 claims description 17
239000012634 fragment Substances 0.000 claims description 15
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 14
238000004113 cell culture Methods 0.000 claims description 14
230000008569 process Effects 0.000 claims description 14
102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 14
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 13
239000008194 pharmaceutical composition Substances 0.000 claims description 13
238000012258 culturing Methods 0.000 claims description 12
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 11
108090000765 processed proteins & peptides Proteins 0.000 claims description 10
108010091221 Lymphotoxin beta Receptor Proteins 0.000 claims description 9
102000018170 Lymphotoxin beta Receptor Human genes 0.000 claims description 9
235000018417 cysteine Nutrition 0.000 claims description 7
235000004279 alanine Nutrition 0.000 claims description 6
241000238631 Hexapoda Species 0.000 claims description 5
230000012010 growth Effects 0.000 claims description 5
238000002703 mutagenesis Methods 0.000 claims description 5
231100000350 mutagenesis Toxicity 0.000 claims description 5
238000004132 cross linking Methods 0.000 claims description 4
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 3
230000001580 bacterial effect Effects 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
-1 TNFR-55 Proteins 0.000 claims description 2
108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 5
102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 5
150000001295 alanines Chemical class 0.000 claims 1
230000015572 biosynthetic process Effects 0.000 claims 1
230000012743 protein tagging Effects 0.000 claims 1
102000005962 receptors Human genes 0.000 description 66
108020003175 receptors Proteins 0.000 description 66
210000004027 cell Anatomy 0.000 description 56
230000027455 binding Effects 0.000 description 40
239000003446 ligand Substances 0.000 description 38
210000004978 chinese hamster ovary cell Anatomy 0.000 description 17
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 17
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
239000000463 material Substances 0.000 description 14
239000001488 sodium phosphate Substances 0.000 description 13
229910000162 sodium phosphate Inorganic materials 0.000 description 13
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 13
102000004083 Lymphotoxin-alpha Human genes 0.000 description 12
108090000542 Lymphotoxin-alpha Proteins 0.000 description 12
239000000499 gel Substances 0.000 description 12
239000000872 buffer Substances 0.000 description 10
230000002829 reductive effect Effects 0.000 description 10
238000001042 affinity chromatography Methods 0.000 description 9
206010028980 Neoplasm Diseases 0.000 description 8
238000010828 elution Methods 0.000 description 8
239000001963 growth medium Substances 0.000 description 8
210000000987 immune system Anatomy 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
102000003959 Lymphotoxin-beta Human genes 0.000 description 7
108090000362 Lymphotoxin-beta Proteins 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
238000004587 chromatography analysis Methods 0.000 description 7
230000003248 secreting effect Effects 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
230000013595 glycosylation Effects 0.000 description 6
238000006206 glycosylation reaction Methods 0.000 description 6
239000002609 medium Substances 0.000 description 6
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
239000000556 agonist Substances 0.000 description 5
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
229910052921 ammonium sulfate Inorganic materials 0.000 description 5
235000011130 ammonium sulphate Nutrition 0.000 description 5
238000003556 assay Methods 0.000 description 5
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
238000000855 fermentation Methods 0.000 description 5
230000004151 fermentation Effects 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
239000012528 membrane Substances 0.000 description 5
238000000926 separation method Methods 0.000 description 5
230000011664 signaling Effects 0.000 description 5
238000010186 staining Methods 0.000 description 5
238000001262 western blot Methods 0.000 description 5
102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 4
238000002835 absorbance Methods 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
230000030833 cell death Effects 0.000 description 4
239000003636 conditioned culture medium Substances 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000028327 secretion Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
108020004414 DNA Proteins 0.000 description 3
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
229930182566 Gentamicin Natural products 0.000 description 3
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
108010035042 Osteoprotegerin Proteins 0.000 description 3
102000008108 Osteoprotegerin Human genes 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
241000700605 Viruses Species 0.000 description 3
238000004847 absorption spectroscopy Methods 0.000 description 3
230000004913 activation Effects 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
239000011324 bead Substances 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
230000037353 metabolic pathway Effects 0.000 description 3
XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
229960005322 streptomycin Drugs 0.000 description 3
238000004114 suspension culture Methods 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
101000830594 Homo sapiens Tumor necrosis factor ligand superfamily member 14 Proteins 0.000 description 2
101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 2
108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000011149 active material Substances 0.000 description 2
238000001261 affinity purification Methods 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000005484 gravity Effects 0.000 description 2
102000051198 human TNFSF14 Human genes 0.000 description 2
230000036737 immune function Effects 0.000 description 2
208000026278 immune system disease Diseases 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
239000012160 loading buffer Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000014616 translation Effects 0.000 description 2
230000035899 viability Effects 0.000 description 2
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
238000012492 Biacore method Methods 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101001011741 Bos taurus Insulin Proteins 0.000 description 1
101000766308 Bos taurus Serotransferrin Proteins 0.000 description 1
SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
102100027207 CD27 antigen Human genes 0.000 description 1
101150013553 CD40 gene Proteins 0.000 description 1
102100024158 Cadherin-10 Human genes 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241001164374 Calyx Species 0.000 description 1
108010076667 Caspases Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
101000762229 Homo sapiens Cadherin-10 Proteins 0.000 description 1
101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 1
101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
101150106931 IFNG gene Proteins 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
101100341510 Mus musculus Itgal gene Proteins 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
102000012883 Tumor Necrosis Factor Ligand Superfamily Member 14 Human genes 0.000 description 1
108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 description 1
102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
235000012538 ammonium bicarbonate Nutrition 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
238000012435 analytical chromatography Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
239000007640 basal medium Substances 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000009920 chelation Effects 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
208000035850 clinical syndrome Diseases 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000002131 composite material Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
230000007783 downstream signaling Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
108010052621 fas Receptor Proteins 0.000 description 1
102000018823 fas Receptor Human genes 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
210000000285 follicular dendritic cell Anatomy 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229940026527 glycine 50 mg Drugs 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
102000052793 human TNFRSF14 Human genes 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000037189 immune system physiology Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
238000000670 ligand binding assay Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
235000020778 linoleic acid Nutrition 0.000 description 1
AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
235000019136 lipoic acid Nutrition 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000006679 metabolic signaling pathway Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000037452 priming Effects 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
238000012207 quantitative assay Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
241000894007 species Species 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
229960002663 thioctic acid Drugs 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
239000004474 valine Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Toxicology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Compounds Of Unknown Constitution (AREA)

SK855-2001A 1998-12-17 1999-12-16 A method for the high level expression of active lymphotoxin-'beta' receptor immunoglobulin chimeric proteins and their purification SK8552001A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11275298P	1998-12-17	1998-12-17
PCT/US1999/029873 WO2000036092A2 (en)	1998-12-17	1999-12-16	METHOD FOR THE HIGH LEVEL EXPRESSION OF ACTIVE LYMPHOTOXIN-β RECEPTOR IMMUNOGLOBULIN CHIMERIC PROTEINS AND THEIR PURIFICATION

Publications (1)

Publication Number	Publication Date
SK8552001A3 true SK8552001A3 (en)	2001-12-03

Family

ID=22345666

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK855-2001A SK8552001A3 (en)	1998-12-17	1999-12-16	A method for the high level expression of active lymphotoxin-'beta' receptor immunoglobulin chimeric proteins and their purification

Country Status (27)

Country	Link
US (3)	US7585946B2 (et)
EP (3)	EP1141248B1 (et)
JP (4)	JP4878676B2 (et)
KR (3)	KR20020013482A (et)
CN (2)	CN101289512A (et)
AT (1)	ATE536372T1 (et)
AU (2)	AU777232B2 (et)
BR (1)	BR9916325B1 (et)
CA (1)	CA2354539A1 (et)
CY (1)	CY1117003T1 (et)
CZ (1)	CZ20012156A3 (et)
DK (2)	DK2374872T4 (et)
EA (1)	EA005270B1 (et)
EE (1)	EE200100324A (et)
ES (1)	ES2554482T5 (et)
HK (1)	HK1223398A1 (et)
HU (1)	HUP0200064A2 (et)
IL (3)	IL143670A0 (et)
IS (1)	IS5959A (et)
NO (1)	NO20012991L (et)
NZ (3)	NZ529276A (et)
PT (1)	PT2374872E (et)
SG (1)	SG123531A1 (et)
SI (1)	SI2374872T2 (et)
SK (1)	SK8552001A3 (et)
TR (2)	TR200504220T2 (et)
WO (1)	WO2000036092A2 (et)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5925351A (en) *	1995-07-21	1999-07-20	Biogen, Inc.	Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7060667B1 (en) *	1998-01-30	2006-06-13	Biogen Idec Ma, Inc.	Treatment of follicular lymphomas using inhibitors of the LT pathway
NZ510560A (en) *	1998-10-09	2003-09-26	Biogen Inc	Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
EP1290027B1 (en)	2000-04-28	2009-09-09	Planet Biotechnology, Inc.	Immunoadhesin for the prevention of rhinovirus infection
US20020168367A1 (en) *	2000-04-28	2002-11-14	Planet Biotechnology Incorporated	Novel immunoadhesins for treating and preventing viral and bacterial diseases
AU2002245272B2 (en) *	2001-01-16	2006-06-29	Regeneron Pharmaceuticals, Inc.	Isolating cells expressing secreted proteins
US20090137416A1 (en)	2001-01-16	2009-05-28	Regeneron Pharmaceuticals, Inc.	Isolating Cells Expressing Secreted Proteins
EP1583503A4 (en) *	2002-12-20	2006-08-09	Biogen Idec Inc	POLYVALENT LYMPHOTOXIN BETA RECEPTOR AGONISTS AND THERAPEUTIC USE THEREOF
PL377731A1 (pl)	2002-12-23	2006-02-06	Bristol-Myers Squibb Company	Sposoby hodowli komórek ssaczych do wytwarzania białka
ATE488600T1 (de)	2002-12-23	2010-12-15	Bristol Myers Squibb Co	Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
WO2005024012A1 (en) *	2003-09-11	2005-03-17	Novozymes A/S	Increased expression of a modified polypeptide
CA2548940A1 (en) *	2003-12-23	2005-07-14	Applied Research Systems Ars Holding N.V.	Process for the production of tumor necrosis factor-binding proteins
US20110038854A1 (en) *	2006-03-30	2011-02-17	University Of Medicine And Dentistry Of New Jersey	Strategy for homo- or hetero-dimerization of various proteins in solution and in cell
AU2007324135B2 (en) *	2006-10-12	2013-06-27	Genentech, Inc.	Antibodies to lymphotoxin-alpha
MX2009004134A (es) *	2006-10-20	2009-08-12	Biogen Idec Inc	Tratamiento de trastornos de desmielinizacion con el receptor de linfotoxina beta soluble.
US8338376B2 (en)	2006-10-20	2012-12-25	Biogen Idec Ma Inc.	Compositions comprising variant LT-B-R-IG fusion proteins
CN101951940A (zh) *	2007-03-15	2011-01-19	比奥根艾迪克Ma公司	自身免疫病的治疗
TW200902708A (en) *	2007-04-23	2009-01-16	Wyeth Corp	Methods of protein production using anti-senescence compounds
WO2009111347A1 (en) *	2008-02-29	2009-09-11	Biogen Idec Ma Inc.	Purified immunoglobulin fusion proteins and methods of their purification
US9540426B2 (en)	2009-10-06	2017-01-10	Bristol-Myers Squibb Company	Mammalian cell culture processes for protein production
JP5980772B2 (ja)	2010-04-26	2016-08-31	ノバルティスアーゲー	改良型細胞培養培地
WO2012176158A1 (en) *	2011-06-24	2012-12-27	Dr. Reddy's Laboratories Limited	Purification of chimeric protein
JP6223338B2 (ja) *	2011-08-17	2017-11-01	アレストレーディングソシエテアノニム	活性型ＴＮＦＲ−Ｆｃ融合タンパク質を製造する方法
WO2014062535A1 (en)	2012-10-15	2014-04-24	Bristol-Myers Squibb Company	Mammalian cell culture processes for protein production
TWI745610B (zh)	2012-11-14	2021-11-11	美商再生元醫藥公司	重組細胞表面捕捉蛋白質
EP3317297A4 (en)	2015-06-30	2019-03-20	Sanford-Burnham Medical Research Institute	BTLA FUSION PROTEIN AGONISTS AND USES THEREOF
KR101936049B1 (ko)	2015-10-15	2019-01-08	(주)알테오젠	IgG Fc 도메인을 가지는 융합 단백질의 생산방법
CN105400721A (zh) *	2015-12-11	2016-03-16	湖南农业大学	一种快速筛选具有抗菌活性芽孢杆菌的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2906096A (en)	1953-12-14	1959-09-29	Pacific Ind Mfg Co	Precision control system for press brakes or the like
WO1991000347A1 (en)	1989-07-04	1991-01-10	Novo Nordisk A/S	Method of producing proteins with fviii activity and/or fviii derivatives
US5605690A (en) *	1989-09-05	1997-02-25	Immunex Corporation	Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US7030080B2 (en)	1990-06-27	2006-04-18	Biogen, Inc.	Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
CA2086264C (en)	1990-06-27	2002-12-24	Jeffrey L. Browning	Surface complexed lymphotoxin
US5795964A (en)	1990-06-27	1998-08-18	Biogen, Inc.	Lymphotoxin-beta and lymphotoxin-beta complexes
WO1992020791A1 (en)	1990-07-10	1992-11-26	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
NZ260103A (en) *	1990-11-30	1996-10-28	Bio Technology General Corp	Somatotropin with alterations in the alpha-helix-1 region
US5656272A (en)	1991-03-18	1997-08-12	New York University Medical Center	Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
IE922437A1 (en)	1991-07-25	1993-01-27	Idec Pharma Corp	Recombinant antibodies for human therapy
US5447851B1 (en) *	1992-04-02	1999-07-06	Univ Texas System Board Of	Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5643570A (en) *	1992-05-19	1997-07-01	Xoma Corporation	BPI-immunoglobulin fusion proteins
EP0620739A4 (en) *	1992-09-15	1997-01-15	Immunex Corp	Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
WO1994006478A1 (en)	1992-09-22	1994-03-31	Medin Corporation	A system for securing medical tools for sterilization
WO1994013804A1 (en)	1992-12-04	1994-06-23	Medical Research Council	Multivalent and multispecific binding proteins, their manufacture and use
US5691196A (en) *	1992-12-31	1997-11-25	American Cyanamid Company	Recombinant nucleic acid containing a response element
US5429746A (en) *	1994-02-22	1995-07-04	Smith Kline Beecham Corporation	Antibody purification
US5856179A (en)	1994-03-10	1999-01-05	Genentech, Inc.	Polypeptide production in animal cell culture
US5726039A (en)	1994-07-21	1998-03-10	Yissum Research Development Co. Of The Hebrew University Of Jerusalem	Vectors and transformed host cells for recombinant protein production at reduced temperatures
US5541087A (en)	1994-09-14	1996-07-30	Fuji Immunopharmaceuticals Corporation	Expression and export technology of proteins as immunofusins
US6312691B1 (en)	1996-01-26	2001-11-06	Jeffrey L. Browning	Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5705364A (en)	1995-06-06	1998-01-06	Genentech, Inc.	Mammalian cell culture process
US5721121A (en) *	1995-06-06	1998-02-24	Genentech, Inc.	Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5925351A (en)	1995-07-21	1999-07-20	Biogen, Inc.	Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) *	1995-07-28	2001-09-18	Northwestern University	Herpes virus entry receptor protein
JP4306813B2 (ja)	1995-09-19	2009-08-05	アスビオファーマ株式会社	動物細胞の新規培養方法
HRP970224A2 (en) *	1996-05-08	1998-04-30	Hoffmann La Roche	TREATMENT OF ASTHMA WITH TNFR-Ig
US6040560A (en) *	1996-10-22	2000-03-21	Philip Morris Incorporated	Power controller and method of operating an electrical smoking system
US7255854B1 (en)	1996-10-25	2007-08-14	Biogen, Inc.	Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
CN101239186A (zh)	1996-10-25	2008-08-13	拜奥根Idec马萨诸塞公司	可溶性β-淋巴毒素受体(LT-β-R)融合蛋白的用途
CA2270913C (en) *	1996-10-30	2011-05-24	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor-like 2
AU5516898A (en) *	1996-12-12	1998-07-03	Genentech Inc.	Hvem polypeptides and uses thereof
US6221608B1 (en) *	1997-01-22	2001-04-24	Ortho Pharmaceutical Corporation	Methods for identifying erythropoietin receptor binding protein
US7060667B1 (en)	1998-01-30	2006-06-13	Biogen Idec Ma, Inc.	Treatment of follicular lymphomas using inhibitors of the LT pathway
CA2325022A1 (en) *	1998-04-16	1999-10-21	Genentech, Inc.	Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
ATE314485T1 (de)	1998-05-29	2006-01-15	Genentech Inc	Zellkulturverfahren für die produktion von glycoproteinen
NZ510560A (en)	1998-10-09	2003-09-26	Biogen Inc	Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
US7294481B1 (en)	1999-01-05	2007-11-13	Immunex Corporation	Method for producing recombinant proteins
US9086881B2 (en)	2012-06-29	2015-07-21	Intel Corporation	Mechanism for facilitating write tracking for following data eye movements across changing thermal conditions in memory systems

1999
- 1999-11-16 TR TR2005/042202005/04220T patent/TR200504220T2/xx unknown
- 1999-12-16 HU HU0200064A patent/HUP0200064A2/hu unknown
- 1999-12-16 KR KR1020017007475A patent/KR20020013482A/ko not_active Ceased
- 1999-12-16 SK SK855-2001A patent/SK8552001A3/sk unknown
- 1999-12-16 PT PT100112127T patent/PT2374872E/pt unknown
- 1999-12-16 ES ES10011212T patent/ES2554482T5/es not_active Expired - Lifetime
- 1999-12-16 WO PCT/US1999/029873 patent/WO2000036092A2/en active Application Filing
- 1999-12-16 CN CNA2008100903968A patent/CN101289512A/zh active Pending
- 1999-12-16 EA EA200100670A patent/EA005270B1/ru not_active IP Right Cessation
- 1999-12-16 AT AT99967350T patent/ATE536372T1/de active
- 1999-12-16 KR KR1020077017658A patent/KR20070091227A/ko not_active Ceased
- 1999-12-16 NZ NZ529276A patent/NZ529276A/en active IP Right Revival
- 1999-12-16 SI SI9931079T patent/SI2374872T2/sl unknown
- 1999-12-16 IL IL14367099A patent/IL143670A0/xx unknown
- 1999-12-16 EP EP99967350A patent/EP1141248B1/en not_active Expired - Lifetime
- 1999-12-16 DK DK10011212.7T patent/DK2374872T4/en active
- 1999-12-16 EP EP10011212.7A patent/EP2374872B2/en not_active Expired - Lifetime
- 1999-12-16 EE EEP200100324A patent/EE200100324A/et unknown
- 1999-12-16 DK DK99967350.2T patent/DK1141248T3/da active
- 1999-12-16 KR KR1020067009941A patent/KR100732934B1/ko not_active Expired - Fee Related
- 1999-12-16 CA CA002354539A patent/CA2354539A1/en not_active Abandoned
- 1999-12-16 NZ NZ538599A patent/NZ538599A/en not_active IP Right Cessation
- 1999-12-16 AU AU23644/00A patent/AU777232B2/en not_active Ceased
- 1999-12-16 JP JP2000588341A patent/JP4878676B2/ja not_active Expired - Lifetime
- 1999-12-16 CN CNB998156957A patent/CN100387708C/zh not_active Expired - Fee Related
- 1999-12-16 EP EP15183033.8A patent/EP3006563A1/en not_active Withdrawn
- 1999-12-16 TR TR2001/01703T patent/TR200101703T2/xx unknown
- 1999-12-16 NZ NZ549623A patent/NZ549623A/en not_active IP Right Cessation
- 1999-12-16 SG SG200200026A patent/SG123531A1/en unknown
- 1999-12-16 CZ CZ20012156A patent/CZ20012156A3/cs unknown
- 1999-12-16 BR BRPI9916325-0A patent/BR9916325B1/pt not_active IP Right Cessation
2001
- 2001-01-23 US US09/767,370 patent/US7585946B2/en not_active Expired - Fee Related
- 2001-05-31 IS IS5959A patent/IS5959A/is unknown
- 2001-06-15 NO NO20012991A patent/NO20012991L/no not_active Application Discontinuation
2005
- 2005-01-07 AU AU2005200042A patent/AU2005200042B2/en not_active Ceased
2009
- 2009-08-17 US US12/542,614 patent/US8283138B2/en not_active Expired - Fee Related
2010
- 2010-03-30 JP JP2010079856A patent/JP2010158252A/ja not_active Withdrawn
- 2010-05-11 IL IL205698A patent/IL205698A/en not_active IP Right Cessation
2012
- 2012-07-19 US US13/553,604 patent/US8709759B2/en not_active Expired - Fee Related
2013
- 2013-02-12 JP JP2013024500A patent/JP5777171B2/ja not_active Expired - Lifetime
- 2013-12-01 IL IL229738A patent/IL229738A0/en unknown
2014
- 2014-09-12 JP JP2014186243A patent/JP2014239697A/ja not_active Withdrawn
2015
- 2015-11-26 CY CY20151101065T patent/CY1117003T1/el unknown
2016
- 2016-10-11 HK HK16111728.8A patent/HK1223398A1/en unknown

Also Published As

Publication number	Publication date
CA2354539A1 (en)	2000-06-22
AU2005200042A1 (en)	2005-02-03
JP5777171B2 (ja)	2015-09-09
US20130196376A1 (en)	2013-08-01
BR9916325B1 (pt)	2011-06-28
DK1141248T3 (da)	2012-03-12
HK1038244A1 (en)	2002-03-08
JP2010158252A (ja)	2010-07-22
JP2013116118A (ja)	2013-06-13
EA005270B1 (ru)	2004-12-30
NZ549623A (en)	2008-05-30
IS5959A (is)	2001-05-31
EA200100670A1 (ru)	2001-12-24
EP2374872B1 (en)	2015-11-25
US8283138B2 (en)	2012-10-09
HUP0200064A2 (en)	2002-05-29
PT2374872E (pt)	2015-12-09
BR9916325A (pt)	2001-10-02
NZ529276A (en)	2005-03-24
IL229738A0 (en)	2014-01-30
KR20060084860A (ko)	2006-07-25
ATE536372T1 (de)	2011-12-15
TR200101703T2 (tr)	2002-05-21
JP2003517277A (ja)	2003-05-27
DK2374872T3 (en)	2015-12-14
AU2005200042B2 (en)	2008-05-01
KR20020013482A (ko)	2002-02-20
EP1141248A2 (en)	2001-10-10
SG123531A1 (en)	2006-07-26
EP1141248B1 (en)	2011-12-07
EP2374872B2 (en)	2019-02-20
ES2554482T3 (es)	2015-12-21
CN100387708C (zh)	2008-05-14
EP2374872A3 (en)	2011-10-19
TR200504220T2 (tr)	2007-04-24
CY1117003T1 (el)	2017-04-05
CN101289512A (zh)	2008-10-22
NZ538599A (en)	2007-11-30
NO20012991D0 (no)	2001-06-15
CZ20012156A3 (cs)	2001-09-12
KR100732934B1 (ko)	2007-06-29
WO2000036092A9 (en)	2002-08-22
KR20070091227A (ko)	2007-09-07
IL143670A0 (en)	2002-04-21
SI2374872T2 (sl)	2019-05-31
US20020039580A1 (en)	2002-04-04
US7585946B2 (en)	2009-09-08
WO2000036092A2 (en)	2000-06-22
NO20012991L (no)	2001-08-17
SI2374872T1 (sl)	2016-03-31
JP4878676B2 (ja)	2012-02-15
IL205698A (en)	2015-11-30
EP3006563A1 (en)	2016-04-13
JP2014239697A (ja)	2014-12-25
AU777232B2 (en)	2004-10-07
DK2374872T4 (en)	2019-04-23
AU2364400A (en)	2000-07-03
CN1333819A (zh)	2002-01-30
US20100136625A1 (en)	2010-06-03
ES2554482T5 (es)	2019-07-18
PL348816A1 (en)	2002-06-17
HK1223398A1 (en)	2017-07-28
US8709759B2 (en)	2014-04-29
EP2374872A2 (en)	2011-10-12
WO2000036092A3 (en)	2000-11-23
EE200100324A (et)	2002-10-15

Publication	Publication Date	Title
SK8552001A3 (en)	2001-12-03	A method for the high level expression of active lymphotoxin-'beta' receptor immunoglobulin chimeric proteins and their purification
JP2721745B2 (ja)	1998-03-04	腫瘍壊死因子―αおよび―βレセプター
WO1996040774A1 (en)	1996-12-19	Complexes of modified lymphotoxins as pharmaceutical preparations
HK1038244B (en)	2012-09-21	A method for the high level expression of the active form of lymphotoxin-beta receptor immunoglobulin fusion proteins and their purification
HK1163733A (en)	2012-09-14	A method for the high level expression of active lymphotoxin-beta receptor immunoglobulin chimeric proteins and their purification
MXPA01006216A (en)	2001-12-13	A method for the high level expression of active lymphotoxin-b receptor immunoglobulin chimeric proteins and their purification
PL203543B1 (pl)	2009-10-30	Sposób ekspresji wysokich poziomów biologicznie aktywnego bia lka fuzyjnego receptor limfotoksyny ß (LT- ß-R)-immunoglobulina, sposób wytwarzania preparatu farmaceutycznego zawieraj acego to bia lko, kompozycja, kompozycja farmaceutyczna i preparat farmaceutyczny

Legal Events

Date	Code	Title	Description
2012-12-03	FB9A	Suspension of patent application procedure